Login to Your Account



EMA's CHMP clears PAH drug Uptravi, myeloma drug Empliciti

By Nuala Moran
Staff Writer

Friday, January 29, 2016

LONDON – Actelion Ltd. added a positive EMA opinion to the FDA and Health Canada approvals for its first-in-class, selective prostacyclin IP receptor agonist, Uptravi (selexipag), for treating pulmonary arterial hypertension (PAH).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription